GSTM1 and breast carcinoma: Another study from China, Liu et al., (2014) found that patients with GSTM1 null genotype related to worse overall survival of breast cancer patients treated with chemotherapy and the hazard ratio for overall survival was 2.00 (95% CI = 1.15 - 3.48).